PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

ABSTRACT:

SUBMITTER: DeZern A 

PROVIDER: S-EPMC9431763 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature